News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, November 2022
Volume17
Issue 11

Lilly and Schrödinger Ink $425 Million Small Molecule Partnership

Eli Lilly and Company will partner with Schrödinger to develop and optimize small molecule compounds.

Schrödinger, a pharmaceutical company that utilizes a specialized computational platform for drug discovery, announced a collaboration with Eli Lilly and Company (Lilly) on Oct. 6, 2022. The collaboration is focused on discovering and optimizing small molecule compounds for a designated target.

According to a company press release, Schrödinger will be responsible for the discovery and optimization process, while Lilly will handle completion of preclinical development, clinical development, and commercialization. Schrödinger will receive an upfront payment and be eligible to receive up to $425 million, contingent on various discovery, development, and commercial milestone payments. Schrödinger will also be eligible to receive low single - to low double-digit royalties on net sales of any products emerging from the collaboration.

Source: Schrödinger

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content